Clinical Trial: A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma

U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07791615) titled 'A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma' on June 14.

Brief Summary: This is an open-label clinical study designed to evaluate the efficacy of Stapokibart combined with immune checkpoint inhibitors in patients with relapsed/refractory lymphoma. Approximately 20 patients with relapsed/refractory lymphoma who have failed prior immune checkpoint inhibitor therapy or failed to achieve remission are planned to be enrolled.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Lymphoma NK T-Cell Lymphoma

Intervention: DRUG: Stapokibart, immune checkpoint ...